fda warning compounded semaglutide safety 2024 2025 The Risks of Products Compounded' weight-loss drugs are a

The glucagon-like peptide-1 receptor agonist, liraglutide, attenuates the progression of overt diabetic nephropathy in type 2 diabetic patients

The addition of glucagon receptor agonism introduces some safety considerations not seen with GLP-1 or dual GLP-1/GIP agonists alone

Excessive pressure pushes the needle deeper, potentially into muscle

phase 2 trial data show significant weight reduction, but it remains unapproved by the MHRA or EMA

The market that grew in that silence now includes a company on a public exchange telling its investors, in a document filed under penalty of securities law, that its unapproved product reaches more Americans than its approved one

Trials are ongoing, with results so far published in The New England Journal of Medicine and other peer-reviewed sources